What is 4D Molecular Therapeutics's asset turnover?

4D Molecular Therapeutics (FDMT) reported asset turnover of 0.2× in Q1 2026.

What is the long-term trend for 4D Molecular Therapeutics's asset turnover?

Over 5 years (2020 to 2025), 4D Molecular Therapeutics's asset turnover has grown at a 12.4% compound annual growth rate (CAGR), from 0.1× to 0.2×.

What does asset turnover mean?

Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.

4D Molecular Therapeutics FDMT Asset turnover

Asset turnover at other companies

Eli LillyLLY

0.7×+0.1×

Regeneron PharmaceuticalsREGN

0.4×0.0×

Vertex PharmaceuticalsVRTX

0.5×0.0×

EyePoint, Inc. EYPT

0×-0.1×

AbbVieABBV

0.5×+0.1×

RegenxbioRGNX

0.2×-0.1×

Other financials

Income statement

See full

Revenue$3.0M+21,664%

Operating income-$73.6M-37.3%

Net income-$68.8M-43.3%

EPS (diluted)-$1.01-17.4%

Balance sheet

See full

Cash & equivalents$72.5M-45.7%

Total debt$20.5M-13.9%

Total equity$451.8M-3.8%

Total assets$512.9M-0.5%

Cash flow

See full

Operating cash flow-$68.1M-42.6%

CapEx--100%

Free cash flow-$68.1M-40.8%

Valuation

See full

Market cap$602.22M+215%

Enterprise value$550.27M+574%

P/S6.8×-8,306×

Profitability

See full

Operating margin-220.1%-110pp

Net margin-174,314.2%-62,763pp

FCF margin-154,209.2%-53,057pp

Returns & leverage

See full

Return on equity-45.4%+29.8pp

Debt / equity0×0.0×

Current ratio9.3×-3.0×

Where this comes from

Calculated from 4D Molecular Therapeutics’s reported figures.

total revenue/total assets=0.2×

Based on trailing twelve months.

The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about 4D Molecular Therapeutics's asset turnover.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is 4D Molecular Therapeutics's asset turnover?: 4D Molecular Therapeutics (FDMT) reported asset turnover of 0.2× in Q1 2026.
What is the long-term trend for 4D Molecular Therapeutics's asset turnover?: Over 5 years (2020 to 2025), 4D Molecular Therapeutics's asset turnover has grown at a 12.4% compound annual growth rate (CAGR), from 0.1× to 0.2×.
What does asset turnover mean?: Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.